Prescribing and administration of CSCI (continuous subcutaneous infusion) furosemide for heart failure patients who are at end of life
Document Purpose and Intended Audience
The aim of these guidelines is to ensure staff are informed and able to manage patients who require treatment with continuous subcutaneous infusions of furosemide at end of life.
These guidelines are suitable for use in both primary community
care and in the in-patient setting.
Christina Radcliffe, Consultant Palliative Medicine St Mary’s Hospice, Birmingham.
Karen Green, Palliative Urgent Response Team Leader Sandwell and West Birmingham NHS Trust.
C. Radcliffe and K. Green reviewed and updated the guidelines.
Subsequently reviewed and endorsed by SPAGG
Reviewed by Dr A Reynolds 2022
Monitoring of guideline implementation locally
(must be within three years)
Dr Jon Tomas
Dr Alice Gray
Date Approved by SPAGG: November 2022
Date submitted to Area Prescribing Committee: N/A
Summary of change/ process
Expansion on importance of MDT decision making
This Guide is intended for use by healthcare professionals and the expectation is that they will use clinical judgement, medical, and nursing knowledge in applying the general principles and recommendations contained within. They are not meant to replace the many available texts on the subject of palliative care.
Some of the management strategies describe the use of drugs outside their licensed indications. They are, however, established and accepted good practice. Please refer to the current BNF for further guidance.
While WMPCPS takes every care to compile accurate information , we cannot guarantee its correctness and completeness and it is subject to change. We do not accept responsibility for any loss, damage or expense resulting from the use of this information.